Properties of calpastatin forms in rat brain  by Melloni, Edon et al.
Properties of calpastatin forms in rat brain
Edon Melloni*, Roberta De Tullio, Monica Averna, Ilaria Tedesco, Franca Salamino,
Bianca Sparatore, Sandro Pontremoli
Institute of Biological Chemistry, University of Genoa, Viale Benedetto XV, 1, 16132 Genoa, Italy
Received 20 May 1998
Abstract Four recombinant calpastatin forms, deduced from
rat brain mRNAs and differing in the number of inhibitory
repetitive domains from zero to four, were expressed and
characterized for their inhibitory efficiency on W- and m-calpain.
Although the most effective one is a truncated calpastatin form
composed of the N-terminal region (domain L) and a single
inhibitory domain, all inhibitors are more active against W-
calpain, but are preferentially degraded and inactivated by m-
calpain. The protein form composed exclusively of a domain L is
deprived of any inhibitory activity but prevents inhibition of
calpain by the other calpastatin forms, indicating that this
calpastatin region could be relevant in the recognition of the
proteinase. A calpastatin form having molecular properties
similar to those of the recombinant truncated calpastatin, has
also been found in rat brain. It does not derive from proteolysis of
a higher molecular mass precursor. The expression of multiple
calpastatin forms may be relevant for the specific modulation of
the different calpain isozymes normally present in a single cell
type.
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1. Introduction
Intracellular calpain activity can be regulated by a natural
protein inhibitor, named calpastatin [1^5]. The primary struc-
ture of calpastatin, deduced from rat liver cDNA [1], indicates
that it is composed of ¢ve domains. The ¢rst, named L, is
located at the N-terminal region of the molecule; the other
four domains, characterized by a high degree of sequence
homology, include the consensus sequence for calpain [6].
Recently we have demonstrated that rat brain contains ¢ve
mRNAs for calpastatin, named RNCAST104, RNCAST103,
RNCAST107, RNCAST23 and RNCAST110, which code
proteins di¡ering in length and in exon composition [7]. In
contrast to the rat liver form, all rat brain calpastatins contain
at the N-terminal region (domain L) an additional amino acid
sequence deriving from exon 4 and two of these forms
(RNCAST104 and RNCAST110 proteins) also contain a se-
quence derived from exon 6, which is absent in the liver pro-
tein. Three of them (RNCAST104, RNCAST103 and
RNCAST107 proteins) contain four repetitive domains,
whereas RNCAST23 protein is composed of a single inhibi-
tory domain. The ¢fth mRNA (RNCAST110) codes a single
putative domain L without inhibitory domains. The other
major di¡erences among these forms are the number and
type of sites for post-translational modi¢cation, due, as indi-
cated above, to the absence or presence of exons 4 and 6. It
has been reported that in di¡erent tissues and mammalian
species domain L of calpastatin is composed of conserved
regions and variable peptide sequences resulting from alterna-
tive splicing [8]. However, a functional role for this domain
has not been identi¢ed previously. The di¡erent regions that
characterize the various rat brain calpastatin forms contain
speci¢c amino acid sequences susceptible of phosphorylation
by protein kinase C together with PEST sequences that have
been suggested to be correlated to the intracellular half-life of
proteins [9].
In this paper, we describe the properties of recombinant rat
brain calpastatins, expressed in E. coli, measuring their inhib-
itory activity and susceptibility to proteolytic degradation by
W- and m-calpain. We also propose a possible function for the
truncated protein molecule containing exclusively the N-ter-
minal region of calpastatin named domain L. Low-Mr calpas-
tatin forms could be produced in the cell by proteolytic deg-
radation of a high-Mr precursor or by expression of a
mutated transcript containing an upstream stop codon. Here
we explore the possibility that the calpain inhibitory activity
found in rat brain and showing low molecular mass, as com-
pared to the ‘normal’ calpastatins containing ¢ve domains,
derives from the expression of a truncated form of calpastatin.
2. Materials and methods
2.1. Preparation of rat brain homogenate
Freshly collected rat brain was suspended in 3 volumes of 0.25 M
sucrose, containing 1 mM EDTA, 1 mM 2-mercaptoethanol, protein-
ase inhibitors (E64, 0.1 mg/ml; pepstatin, 100 WM; antipain, 10 WM;
phenylmethylsulfonyl £uoride, 1 mM; leupeptin, 100 Wg/ml and cal-
pain inhibitor I, 50 WM) and disrupted by using a Potter Elvehjem
homogenizer. The particulate material was discarded by centrifuga-
tion at 10 000Ug for 20 min; the clear supernatant was collected and
immediately heated at 90‡C for 3 min. All denatured proteins were
removed by centrifugation.
2.2. Puri¢cation and assay of calpains and calpastatins
W-Calpain and m-calpain were puri¢ed from rat brain and assayed
as previously described [10]. One unit of enzyme activity is de¢ned as
the amount that releases 1 Wmol/h of free K-amino groups under the
speci¢ed conditions.
Calpastatin was assayed as previously described [11]. One unit of
calpastatin activity is de¢ned as the amount required to inhibit 1 unit
of calpain activity.
2.3. Expression of calpastatins as fusion proteins in E. coli
Five cDNAs for calpastatin were obtained from rat brain mRNA
by RT-PCR as reported previously [7]. The cDNA fragments coding
for RNCAST104, RNCAST107, RNCAST110 and RNCAST23 cal-
pastatins were ampli¢ed by using the sense primer 5P-TGGGATC-
CATGAGTACCACAGGAGCTAAGG, containing a BamHI restric-
tion site at the 5P end and the antisense primer 5P-GCGAATT-
CAAAAGTCACCATCCACCAGC, containing an EcoRI restriction
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site at the 5P end. Each insert was ligated into an EcoRI/BamHI cut
pGEX2T expression vector (Amersham-Pharmacia Biotech.) and E.
coli TOP 10FP cells were transfected by electroporation (Bio-Rad
Gene Pulser). Recombinant plasmids were then sequenced by the
dideoxynucleotide chain termination method [12] from both strands.
Expression and puri¢cation of GST-calpastatins were carried out ac-
cording to instructions from the manufacturer. Where indicated,
GST-calpastatins were cleaved with thrombin [13] followed by isola-
tion of recombinant calpastatins by a⁄nity chromatography on glu-
tathione-Sepharose columns.
2.4. Preparation of the anti-RNCAST23 monoclonal antibody (mAb)
To produce monoclonal antibodies against RNCAST23 calpastatin,
GST-RNCAST23 fusion protein was coupled with hemocyanin [14],
emulsi¢ed with complete Freund’s adjuvant and injected intraperito-
neally into mice. Two booster injections were administered at 10-day
intervals; the third injection was done using isolated RNCAST23
calpastatin as an antigen. Three days after the last immunization
the animals’ spleen was harvested. All subsequent operations were
carried out as reported [15]. Clones with the highest capacity to pro-
duce anti-RNCAST23 mAb were identi¢ed with a solid-phase radio-
immunoassay, as previously described [16].
3. Results
To de¢ne the functional properties of the putative calpas-
tatin proteins coded by mRNAs identi¢ed previously in rat
brain [7], we expressed four of them in E. coli cells. Speci¢-
cally, RNCAST104, RNCAST107, RNCAST23 and
RNCAST110 were expressed, whereas RNCAST103 was not
expressed due to its high similarity to the other two high Mr
calpastatin forms. The recombinant proteins were recovered
as fusion proteins with glutathione S-transferase (GST) and
calpastatins were then isolated by digestion of the fusion pro-
tein with thrombin and further puri¢ed to homogeneity. The
resulting protein solutions were analyzed in SDS-PAGE (Fig.
1) and, although the calculated molecular mass of the di¡erent
calpastatin forms was lower than that shown on SDS-PAGE
as reported previously [1], the di¡erences in the apparent mo-
lecular mass were consistent with the length of the coding
region of the cDNAs utilized for cell transfection.
In fact, RNCAST104 and RNCAST107 proteins showed
the highest molecular mass, RNCAST23 (low Mr form)
showed an Mr of approximately 30 kDa, and RNCAST110
an Mr of approximately 15 kDa.
These calpastatin forms were then tested for their inhibitory
e⁄ciency on homologous W- and m-calpain. As shown in Fig.
2A, the RNCAST23 calpastatin was the more e⁄cient form in
inhibiting both proteinases, although with a higher e¡ective-
ness on W-calpain. RNCAST104 and RNCAST107 (Fig.
2B,C) were also more active on W-calpain, whereas
RNCAST110, the form deprived of inhibitory domains, was
completely ine⁄cient against both calpain forms (data not
shown). At molar basis, RNCAST23 calpastatin was 2.78 or
3.95 times more active as compared to RNCAST104 and
RNCAST107, respectively.
In order to verify the hypothesis that domain L may be
involved in the recognition of the calpain molecule by calpas-
tatin, we measured the e¡ect of RNCAST110 protein on the
inhibitory e⁄ciency of the active calpastatin forms. As shown
in Fig. 3A, addition of RNCAST110 protein resulted in a
progressive decrease of the inhibition promoted by
RNCAST104, RNCAST107 and RNCAST23 on W-calpain;
65^75% of the inhibitory activity was abolished at the highest
concentrations of RNCAST110 protein used. The e¡ect on m-
calpain was much less pronounced (Fig. 3B), indicating that
RNCAST110 has a higher a⁄nity for W-calpain. Although
such a protein has not yet been identi¢ed in any tissue, it
can be postulated that its expression may be required to re-
duce the actual level of calpain inhibitor activity exerted by
the excess of calpastatin that has been reported to be normally
present in the cell [17].
It is known that calpastatin from di¡erent sources can be
degraded by calpain isoforms and that m-calpains can cause
inactivation of the inhibitor following the formation of the
enzyme-inhibitor complex [11]. We then analyzed if the active
recombinant calpastatins were equally sensitive to degradation
by homologous calpains. As shown in Fig. 4A, W-calpain was
ine¡ective in promoting inactivation of the recombinant cal-
pastatin forms. On the contrary, exposure to m-calpain pro-
moted a progressive inactivation of the calpastatin forms;
approximately 50% of the original inhibitory activity of all
three calpastatins was lost within one hour.
To establish if multiple calpastatin forms were expressed in
rat brain, crude extracts from this tissue were prepared in the
presence of a mixture of protease inhibitors, immediatly
heated at 90‡C to avoid, as much as possible, the proteolysis
of native calpastatin and submitted to SDS-PAGE. The gel
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Fig. 1. SDS-PAGE of puri¢ed recombinant calpastatins. Recombi-
nant calpastatins were expressed and puri¢ed as described in Section
2. Samples (3^7 Wg) were submitted to 9% SDS-PAGE and Coo-
massie-stained. The arrows indicate the positions of molecular
weight markers (glycogen phosphorylase, 92 kDa; carbonic anhy-
drase, 29 kDa; cytochrome c, 13 kDa). Lane 1: RNCAST107; lane
2: RNCAST104; lane 3: RNCAST23; lane 4: RNCAST110.
Fig. 2. Inhibitory e⁄ciency of recombinant calpastatins on homolo-
gous W-calpain and m-calpain. Puri¢ed rat brain W-calpain (b) or m-
calpain (a) were incubated with the indicated amounts of the di¡er-
ent calpastatins in the standard conditions described in Section 2.
A, B and C refer to RNCAST23, RNCAST104 and RNCAST107,
respectively.
E. Melloni et al./FEBS Letters 431 (1998) 55^5856
was then cut in 2-mm slices, proteins were eluted from each
slice and assayed for the presence of calpastatin activity. Two
peaks of calpain inhibitor activity were identi¢ed (Fig. 5), the
¢rst one showing a molecular mass identical to that of the
high-Mr recombinant calpastatins (RNCAST104 or
RNCAST107), the second one having the mass of the low-
Mr recombinant calpastatin RNCAST23. Identical results
were obtained using di¡erent tissue extracting media, supple-
mented with a variety of protease inhibitors with or without
the heat step (data not shown), indicating that a low-Mr cal-
pain inhibitor is constitutively expressed in rat brain. To es-
tablish the molecular nature of this calpain inhibitor form, its
reactivity with an anti-RNCAST23 monoclonal antibody was
assayed in a solid phase radioimmunoassay. As shown in Fig.
5, a peak of immunoreactivity, showing an electrophoretic
migration corresponding to that of the recombinant
RNCAST23 calpastatin, was detected, indicating a high de-
gree of similarity between the form coded by the RNCAST23
transcript and the low-Mr calpastatin identi¢ed in rat brain.
4. Discussion
Evidence is found that the calpain family, in addition to the
ubiquitous forms, is composed of many other members in-
cluding tissue speci¢c calpains [18]. Recently, genomic sequen-
ces coding for calpain-like proteins, lacking the calmodulin
domain, have also been identi¢ed [19,20]. It is di⁄cult to
conceive that regulation of multiple calpain forms, with di¡er-
ent molecular characteristics and speci¢city, could be accom-
plished by a single intracellular protein inhibitor form, namely
calpastatin. The presence of di¡erent partial transcripts for
calpastatin has been described in several mammalian tissues,
indicating that multiple forms of the natural protein calpain
inhibitor, produced by alternative splicing or derived from
mutations [8,21], could provide speci¢c calpain inhibitory
equipment of the cell. Moreover, post-translational modi¢ca-
tions [10] could also be involved in modulating each calpas-
tatin form in both e⁄ciency and calpain target selectivity. We
have recently reported the identi¢cation of ¢ve mRNAs in rat
brain, coding calpastatin forms having di¡erent primary struc-
tures in the N-terminal domain, followed by a number of
inhibitory repeats from zero to four [7].
The proteins corresponding to rat brain calpastatin
mRNAs have now been expressed in E. coli and characterized
at a functional level. It seems particularly relevant that the
more e⁄cient form is the calpastatin containing a single in-
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Fig. 5. Calpastatin forms present in rat brain. An aliquot of rat
brain homogenate, prepared as described in Section 2 and corre-
sponding to 50 Wg of protein, was submitted to SDS-PAGE. After
the electrophoretic run, the gel was washed twice (5 min each) in
50 mM sodium borate bu¡er, pH 7.5, containing 0.1 mM EDTA,
0.5 mM 2-mercaptoethanol and 20% methanol, to remove the excess
of SDS, and a third time with the same bu¡er solution, without
methanol. The gel was then cut into 0.2-cm slices which were ho-
mogenized in 0.3 ml of the last gel washing bu¡er. The gel was re-
moved by centrifugation and the clear supernatants were collected.
In order to obtain a complete protein elution the extraction proce-
dures were repeated three times. Finally the solutions obtained from
a single slice were combined and aliquots were used for the assay of
calpastatin activity on W-calpain (b) or for the presence of calpasta-
tin immunoreactive molecules by a solid-phase radioimmunoassay,
using a monoclonal antibody directed against RNCAST23 recombi-
nant protein (E).
Fig. 3. E¡ect of RNCAST110 recombinant protein on the inhibition
of W-calpain and m-calpain by RNCAST107, RNCAST104 and
RNCAST23 calpastatins. Puri¢ed rat brain W-calpain (A) or m-cal-
pain (B) were incubated, as described in Section 2, in the presence
of puri¢ed RNCAST23 (b), RNCAST104 (a) or RNCAST107 (R)
calpastatin in an amount capable to promote 50% of proteinase in-
hibition. The indicated quantities of RNCAST110 protein were also
added to the incubation mixtures. The calpain inhibition is ex-
pressed as percentage of the original value, measured in the absence
of RNCAST110 protein.
Fig. 4. Inactivation of calpastatins by W-calpain and m-calpain. Rat
brain W-calpain (A) or m-calpain (B) were incubated with equimolar
amounts of recombinant calpastatins in the conditions speci¢ed pre-
viously [10]. At the indicated times, the incubation mixtures were
heated at 90‡C for 2 min to inactivate calpain and the residual ac-
tivities of RNCAST23 (b), RNCAST104 (a), RNCAST107 (R) cal-
pastatins were assayed as described in Section 2.
E. Melloni et al./FEBS Letters 431 (1998) 55^58 57
hibitory domain (low-Mr form) as compared to those contain-
ing the four repeats (high-Mr forms). These ¢ndings suggest
that only one inhibitory domain is operating with high e⁄-
ciency in each calpastatin molecule, the other repeats being
silent or much less active. Moreover, the physical and chem-
ical parameters, evaluated with the PHYSCHEM program on
each recombinant calpastatin, reveal that the active calpain
inhibitors can be considered stable proteins, showing a com-
parable instability index of approximately 37^48 [22], whereas
the RNCAST110 protein, that contains only the N-terminal
region of calpastatin and lacks inhibitory domains and has an
instability index over 60, is predicted as potentially instable.
The competition found between the RNCAST110 protein
and the other recombinant calpastatins may provide new sug-
gestions concerning the mechanism of formation of the en-
zyme-inhibitor complex, as well as the possible role of this
moiety of the calpastatin molecule in the modulation of its
inhibitory activity. The highest speci¢city of this calpastatin
N-terminal fragment for W-calpain is in agreement with the
observation that the inhibitory e⁄ciency of all the rat brain
recombinant calpastatins is lower on m-calpain which is, on
the contrary, the form that promotes proteolytic inactivation
of all calpastatin isoforms.
Digestion and inactivation of calpastatin by m-calpain
could be related to a postulated ‘pathological function’ of
calpain, resulting from an indiscriminate activation of the
proteinase facilitated by a decrease in the intracellular level
of calpastatin [23]. A number of reports suggest that calpain is
involved in many pathological disorders [5,24,25]. A multi-
plicity of calpastatin forms may be required to maintain prop-
er control on the catalytic activity of di¡erent calpain iso-
forms expressed by cells and hence preventing the onset of
irreversible functional damages. We have reported previously
that in rat skeletal muscle [26] and in rat brain [10] a phos-
phorylation/dephosphorylation process is involved in the
modulation of calpastatin e⁄ciency and selectivity. The iden-
ti¢cation of multiple calpastatin mRNAs in rat brain and the
evidence that at least two of these forms are expressed repre-
sents a further ampli¢cation of the number of the calpastatin
types that could be produced in a single cell, resulting in a
more accurate regulation of proteinase activity.
It will be of interest to establish if multiple forms of calpas-
tatin are also present in other tissues and if the question
whether the expression of the calpastatin forms is correlated
to a speci¢c function of calpain played a role in these tissues.
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